Recent advances in imaging of dopaminergic neurons for evaluation of neuropsychiatric disorders

Journal of Biomedicine and Biotechnology

Volumn 2012, Issue , 2012, Pages

  Shen, Lie Hang ^a   Liao, Mei Hsiu ^a   Tseng, Yu Chin ^a  

^a INSTITUTE OF NUCLEAR ENERGY RESEARCH   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

2 CARBOMETHOXY 3 (4 IODOPHENYL)TROPANE I 123; 2BETA CARBOMETHOXY 3BETA ITROPANE C 11; 3,4 DIHYDROXY 6 FLUOROPHENYLALANINE F 18; 6 FLUORODOPAMINE F 18; 8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE C 11; [2 [[2 [[[3 (4 CHLOROPHENYL) 8 METHYL 8 AZABICYCLO[3.2.1]OCT 2 YL]METHYL](2 MERCAPTOETHYL)AMINO]ETHYL]AMINO]ETHANETHIOLATO]OXOTECHNETIUM TC 99M; ALTROPANE; ALTROPANE I 123; DOPAMINE; FLUORODEOXYGLUCOSE F 18; FLUOROMETHYLTYROSINE F 18; FLUOROPROPYL 2' CARBOMETHOXY 3 (4 IODOPHENYL) I 123; NEUROLEPTIC AGENT; RACLOPRIDE C 11; TEBOROXIME TC 99M; TRACER; UNCLASSIFIED DRUG;

ATTENTION DEFICIT DISORDER; BRAIN FUNCTION; DOPAMINERGIC ACTIVITY; DOPAMINERGIC NERVE CELL; DOPAMINERGIC SYSTEM; DRUG ABUSE; HUMAN; MENTAL DISEASE; MOLECULAR IMAGING; NEUROIMAGING; PARKINSON DISEASE; PARKINSONISM; POSITRON EMISSION TOMOGRAPHY; REVIEW; SCHIZOPHRENIA; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; ADDICTION; ANIMAL; METHODOLOGY; PATHOLOGY; SCINTISCANNING;

ANIMALS; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; DOPAMINERGIC NEURONS; HUMANS; MENTAL DISORDERS; MOLECULAR IMAGING; PARKINSON DISEASE; POSITRON-EMISSION TOMOGRAPHY; RADIOACTIVE TRACERS; SCHIZOPHRENIA; SUBSTANCE-RELATED DISORDERS; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 84861060154     PISSN: 11107243     EISSN: 11107251     Source Type: Journal    
DOI: 10.1155/2012/259349     Document Type: Review

References (120)

1. Wong D. F., Grnder G., Brasic J. R., Brain imaging research: does the science serve clinical practice? International Review of Psychiatry 2007 19 5 541 558 (Pubitemid 47493740)
2. Metter F. A., Guiberteau M. J., Radioactivity, radionuclides, and radiopharmaceuticals Essentials of Nuclear Medicine Imaging 2006 5th chapter 1 Saunders, Elsevier 1 13
3. Metter F. A., Guiberteau M. J., Positron emission tomography (PET) imaging Essentials of Nuclear Medicine Imaging 2006 5th chapter 13 Saunders, Elsevier 359 423
4. Weissleder R., Mahmood U., Molecular imaging Radiology 2001 219 2 316 333 (Pubitemid 32336342)
5. Fumita M., Innis R. B., Neuropsychopharmacology: The Fifth Generation of Progress 2002 1st Philadelphia, Pa, USA Lippincott Williams Wilkins
6. Heiss W. D., Herholz K., Brain receptor imaging Journal of Nuclear Medicine 2006 47 2 302 312 (Pubitemid 46780896)
7. Sioka C., Fotopoulos A., Kyritsis A. P., Recent advances in PET imaging for evaluation of Parkinson's disease European Journal of Nuclear Medicine and Molecular Imaging 2010 37 8 1594 1603
8. Pavese N., Brooks D. J., Imaging neurodegeneration in Parkinson's disease Biochimica et Biophysica Acta 2009 1792 7 722 729
9. Pavese N., Kiferle L., Piccini P., Neuroprotection and imaging studies in Parkinson's disease Parkinsonism and Related Disorders 2010 15 supplement 4 S33 S37
10. Seibyl J. P., Imaging studies in movement disorders Seminars in Nuclear Medicine 2003 33 2 105 113 (Pubitemid 36577053)
11. Brooks D. J., Frey K. A., Marek K. L., Oakes D., Paty D., Prentice R., Shults C. W., Stoessl A. J., Assessment of neuroimaging techniques as biomarkers of the progression of Parkinson's disease Experimental Neurology 2003 184 supplement 1 S68 S79
12. Rinne J. O., Laihinen A., Ngren K., Ruottinen H., Ruotsalainen U., Rinne U. K., PET examination of the monoamine transporter with [ 11 C] -CIT and [ 11 C] -CFT in early Parkinson's disease Synapse 1995 21 2 97 103
13. Rinne J. O., Ruottinen H., Bergman J., Haaparanta M., Sonninen P., Solin O., Usefulness of a dopamine transporter PET ligand [ 18 F] -CFT in assessing disability in Parkinson's disease Journal of Neurology Neurosurgery and Psychiatry 1999 67 6 737 741
14. Rinne J. O., Nurmi E., Ruottinen H. M., Bergman J., Eskola O., Solin O., [ 18 F]FDOPA and [ 18 F]CFT are both sensitive PET markers to detect presynaptic dopaminergic hypofunction in early Parkinson's disease Synapse 2001 40 3 193 200 (Pubitemid 32322212)
15. Meegalla S. K., Plssl K., Kung M. P., Chumpradit S., Stevenson D. A., Kushner S. A., McElgin W. T., Mozley P. D., Kung H. F., Synthesis and characterization of technetium-99m-labeled tropanes as dopamine transporter-imaging agents Journal of Medicinal Chemistry 1997 40 1 9 17 (Pubitemid 27027260)
16. Kung M. P., Stevenson D. A., Plssl K., Meegalla S. K., Beckwith A., Essman W. D., Mu M., Lucki I., Kung H. F., [ 99 m Tc ]TRODAT-1: a novel technetium-99m complex as a dopamine transporter imaging agent European Journal of Nuclear Medicine 1997 24 4 372 380 (Pubitemid 27183040)
17. Ribeiro M. J., Vidailhet M., Loc'h C., Dupel C., Nguyen J. P., Ponchant M., Dollé F., Peschanski M., Hantraye P., Cesaro P., Samson Y., Remy P., Dopaminergic function and dopamine transporter binding assessed with positron emission tomography in Parkinson disease Archives of Neurology 2002 59 4 580 586 (Pubitemid 34289961)
18. Booij J., Tissingh G., Winogrodzka A., Boer G. J., Stoof J. C., Wolters E. C., van Royen E. A., Practical benefit of [ 123 I]FP-CIT SPET in the demonstration of the dopaminergic deficit in Parkinson's disease European Journal of Nuclear Medicine 1997 24 1 68 71 (Pubitemid 27122444)
19. Cummings J. L., Henchcliffe C., Schaier S., Simuni T., Waxman A., Kemp P., The role of dopaminergic imaging in patients with symptoms of dopaminergic system neurodegeneration Brain 2011 134 11 3146 3166
20. Ravina B., Eidelberg D., Ahlskog J. E., Albin R. L., Brooks D. J., Carbon M., Dhawan V., Feigin A., Fahn S., Guttman M., Gwinn-Hardy K., McFarland H., Innis R., Katz R. G., Kieburtz K., Kish S. J., Lange N., Langston J. W., Marek K., Morin L., Moy C., Murphy D., Oertel W. H., Oliver G., Palesch Y., Powers W., Seibyl J., Sethi K. D., Shults C. W., Sheehy P., Stoessl A. J., Holloway R., The role of radiotracer imaging in Parkinson disease Neurology 2005 64 2 208 215
21. Fernandez H. H., Friedman J. H., Fischman A. J., Noto R. B., Lannon M. C., Is altropane SPECT more sensitive to fluoroDOPA PET for detecting early Parkinson's disease? Medical Science Monitor 2001 7 6 1339 1343 (Pubitemid 33134674)
22. Nurmi E., Ruottinen H. M., Bergman J., Haaparanta M., Solin O., Sonninen P., Rinne J. O., Rate of progression in Parkinson's disease: a 6-[ 18 F]fluoro-L-dopa PET study Movement Disorders 2001 16 4 608 615 (Pubitemid 36040839)
23. Huang W. S., Chiang Y. H., Lin J. C., Chou Y. H., Cheng C. Y., Liu R. S., Crossover study of 99 m Tc -TRODAT-1 SPECT and 18 F-FDOPA PET in Parkinson's disease patients Journal of Nuclear Medicine 2003 44 7 999 1005
24. Freed C. R., Greene P. E., Breeze R. E., Tsai W. Y., DuMouchel W., Kao R., Dillon S., Winfield H., Culver S., Trojanowski J. Q., Eidelberg D., Fahn S., Transplantation of embryonic dopamine neurons for severe Parkinson's disease New England Journal of Medicine 2001 344 10 710 719 (Pubitemid 32204988)
25. Ma Y., Tang C., Chaly T., Greene P., Breeze R., Fahn S., Freed C., Dhawan V., Eidelberg D., Dopamine cell implantation in Parkinson's disease: long-term clinical and 18 F-FDOPA PET outcomes Journal of Nuclear Medicine 2010 51 1 7 15
26. Marks W. J. Jr., Ostrem J. L., Verhagen L., Starr P. A., Larson P. S., Bakay R. A., Taylor R., Cahn-Weiner D. A., Stoessl A. J., Olanow C. W., Bartus R. T., Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2-neurturin) to patients with idiopathic Parkinson's disease: an open-label, phase I trial The Lancet Neurology 2008 7 5 400 408
27. Ernst M., Zametkin A. J., Matochik J. A., Pascualvaca D., Jons P. H., Cohen R. M., High midbrain [ 18 F]DOPA accumulation in children with attention deficit hyperactivity disorder American Journal of Psychiatry 1999 156 8 1209 1215 (Pubitemid 29374881)
28. Patel N. H., Vyas N. S., Puri B. K., Nijran K. S., Al-Nahhas A., Positron emission tomography in schizophrenia: a new perspective Journal of Nuclear Medicine 2010 51 4 511 520
29. Howes O. D., Montgomery A. J., Asselin M. C., Murray R. M., Valli I., Tabraham P., Bramon-Bosch E., Valmaggia L., Johns L., Broome M., McGuire P. K., Grasby P. M., Elevated striatal dopamine function linked to prodromal signs of schizophenia Archives of General Psychiatry 2009 66 1 13 20
30. Eberling J. L., Jagust W. J., Christine C. W., Starr P., Larson P., Bankiewicz K. S., Aminoff M. J., Results from a phase I safety trial of hAADC gene therapy for Parkinson disease Neurology 2008 70 21 1980 1983
31. Muramatsu S. I., Fujimoto K. I., Kato S., Mizukami H., Asari S., Ikeguchi K., Kawakami T., Urabe M., Kume A., Sato T., Watanabe E., Ozawa K., Nakano I., A phase I study of aromatic l-amino acid decarboxylase gene therapy for Parkinson's disease Molecular Therapy 2010 18 9 1731 1735
32. Shi J., Zhao L. Y., Copersino M. L., Fang Y. X., Chen Y., Tian J., Deng Y., Shuai Y., Jin J., Lu L., PET imaging of dopamine transporter and drug craving during methadone maintenance treatment and after prolonged abstinence in heroin users European Journal of Pharmacology 2008 579 13 160 166
33. Spencer T. J., Biederman J., Madras B. K., Faraone S. V., Dougherty D. D., Bonab A. A., Fischman A. J., In vivo neuroreceptor imaging in attention-deficit/hyperactivity disorder: a focus on the dopamine transporter Biological Psychiatry 2005 57 11 1293 1300 (Pubitemid 40798548)
34. Quinn N., A multicenter assessment of dopamine transporter imaging with DOPASCAN/SPECT in parkinsonism Neurology 2001 57 4 746 747 (Pubitemid 32783025)
35. Asenbaum S., Pirker W., Angelberger P., Bencsits G., Pruckmayer M., Brucke T., [ 123 I] -CIT and SPECT in essential tremor and Parkinson's disease Journal of Neural Transmission 1998 105 1012 1213 1228 (Pubitemid 29017402)
36. Malison R. T., Best S. E., van Dyck C. H., McCance E. F., Wallace E. A., Lamelle M., Baldwin R. M., Seibyl J. P., Price L. H., Kosten T. R., Innis R. B., Elevated striatal dopamine transporters during acute cocaine abstinence as measured by [ 123 I] -CIT SPECT American Journal of Psychiatry 1998 155 6 832 834 (Pubitemid 28252667)
37. Jacobsen L. K., Staley J. K., Malison R. T., Zoghbi S. S., Seibyl J. P., Kosten T. R., Innis R. B., Elevated central serotonin transporter binding availability in acutely abstinent cocaine-dependent patients American Journal of Psychiatry 2000 157 7 1134 1140 (Pubitemid 30432496)
38. van Dyck C. H., Quinlan D. M., Cretella L. M., Staley J. K., Malison R. T., Baldwin R. M., Seibyl J. P., Innis R. B., Unaltered dopamine transporter availability in adult attention deficit hyperactivity disorder American Journal of Psychiatry 2002 159 2 309 312 (Pubitemid 34126913)
39. Booij J., Speelman J. D., Horstink M. W. I. M., Wolters E. C., The clinical benefit of imaging striatal dopamine transporters with [ 123 I]FP-CIT SPET in differentiating patients with presynaptic parkinsonism from those with other forms of parkinsonism European Journal of Nuclear Medicine 2001 28 3 266 272
40. Koch W., Hamann C., Radau P. E., Tatsch K., Does combined imaging of the pre- and postsynaptic dopaminergic system increase the diagnostic accuracy in the differential diagnosis of parkinsonism? European Journal of Nuclear Medicine and Molecular Imaging 2007 34 8 1265 1273 (Pubitemid 47290664)
41. Plotkin M., Amthauer H., Klaffke S., Khn A., Ldemann L., Arnold G., Wernecke K. D., Kupsch A., Felix R., Venz S., Combined 123 I-FP-CIT and 123 I-IBZM SPECT for the diagnosis of parkinsonian syndromes: study on 72 patients Journal of Neural Transmission 2005 112 5 677 692 (Pubitemid 40591200)
42. Benamer T. S., Patterson J., Grosset D. G., Booij J., de Bruin K., van Royen E., Speelman J. D., Horstink M. H. I. M., Sips H. J. W. A., Dierckx R. A., Versijpt J., Decoo D., van der Linden C., Hadley D. M., Doder M., Lees A. J., Costa D. C., Gacinovic S., Oertel W. H., Pogarell O., Hoeffken H., Joseph K., Tatsch K., Schwarz J., Ries V., Accurate differentiation of parkinsonism and essential tremor using visual assessment of [ 123 I]-FP-CIT SPECT imaging: the [ 123 I]-FP-CIT study group Movement Disorders 2000 15 3 503 510 (Pubitemid 30333223)
43. Colloby S., O'Brien J., Functional imaging in Parkinson's disease and dementia with Lewy bodies Journal of Geriatric Psychiatry and Neurology 2004 17 3 158 163 (Pubitemid 39128225)
44. O'Brien J. T., Colloby S., Fenwick J., Williams E. D., Firbank M., Burn D., Aarsland D., McKeith I. G., Dopamine transporter loss visualized with FP-CIT SPECT in the differential diagnosis of dementia with lewy bodies Archives of Neurology 2004 61 6 919 925 (Pubitemid 38747333)
45. Larisch R., Sitte W., Antke C., Nikolaus S., Franz M., Tress W., Mller H. W., Striatal dopamine transporter density in drug naive patients with attention-deficit/hyperactivity disorder Nuclear Medicine Communications 2006 27 3 267 270 (Pubitemid 44391815)
46. Hesse S., Ballaschke O., Barthel H., Sabri O., Dopamine transporter imaging in adult patients with attention-deficit/hyperactivity disorder Psychiatry Research 2009 171 2 120 128
47. Vles J. S. H., Feron F. J. M., Hendriksen J. G. M., Jolles J., van Kroonenburgh M. J. P. G., Weber W. E. J., Methylphenidate down-regulates the dopamine receptor and transporter system in children with Attention Deficit Hyperkinetic Disorder (ADHD) Neuropediatrics 2003 34 2 77 80 (Pubitemid 36597126)
48. Mateos J. J., Lomea F., Parellada E., Mireia F., Fernandez-Egea E., Pavia J., Prats A., Pons F., Bernardo M., Lower striatal dopamine transporter binding in neuroleptic-naive schizophrenic patients is not related to antipsychotic treatment but it suggests an illness trait Psychopharmacology 2007 191 3 805 811 (Pubitemid 46355894)
49. Huang W. S., Lin S. Z., Lin J. C., Wey S. P., Ting G., Liu R. S., Evaluation of early-stage Parkinson's disease with 99 m Tc -TRODAT-1 imaging Journal of Nuclear Medicine 2001 42 9 1303 1308 (Pubitemid 32852603)
50. Weng Y. H., Yen T. C., Chen M. C., Kao P. F., Tzen K. Y., Chen R. S., Wey S. P., Ting G., Lu C. S., Sensitivity and specificity of 99 m Tc -TRODAT-1 SPECT imaging in differentiating patients with idiopathic Parkinson's disease from healthy subjects Journal of Nuclear Medicine 2004 45 3 393 401 (Pubitemid 47618611)
51. Chen C. M., Lin C. H., Juan H. F., Hu F. J., Hsiao Y. C., Chang H. Y., Chao C. Y., Chen I. C., Lee L. C., Wang T. W., Chen Y. T., Chen Y. T., Lee-Chen G. J., Wu Y. R., ATP13A2 variability in Taiwanese Parkinson's disease American Journal of Medical Genetics B 2011 156 6 720 729
52. Lu C. S., Weng Y. H., Chen M. C., Chen R. S., Tzen K. Y., Wey S. P., Ting G., Chang H. C., Yen T. C., 99 m Tc -TRODAT-1 imaging of multiple system atrophy Journal of Nuclear Medicine 2004 45 1 49 55 (Pubitemid 47611607)
53. Tzen K. Y., Lu C. S., Yen T. C., Wey S. P., Ting G., Differential diagnosis of Parkinson's disease and vascular parkinsonism by 99 m Tc -TRODAT-1 Journal of Nuclear Medicine 2001 42 3 408 413 (Pubitemid 32207389)
54. Huang C. C., Yen T. C., Weng Y. H., Lu C. S., Normal dopamine transporter binding in dopa responsive dystonia Journal of Neurology 2002 249 8 1016 1020
55. Lin W. Y., Lin K. J., Weng Y. H., Yen T. C., Shen L. H., Liao M. H., Lu C. S., Preliminary studies of differential impairments of the dopaminergic system in subtypes of progressive supranuclear palsy Nuclear Medicine Communications 2010 31 11 974 980
56. Weng Y. H., Chou Y. H. W., Wu W. S., Lin K. J., Chang H. C., Yen T. C., Chen R. S., Wey S. P., Lu C. S., PINK1 mutation in Taiwanese early-onset parkinsonism: clinical, genetic, and dopamine transporter studies Journal of Neurology 2007 254 10 1347 1355
57. Yen T. C., Tzen K. Y., Chen M. C., Chou Y. H. W., Chen R. S., Chen C. J., Wey S. P., Ting G., Lu C. S., Dopamine transporter concentration is reduced in asymptomatic Machado-Joseph disease gene carriers Journal of Nuclear Medicine 2002 43 2 153 159 (Pubitemid 34151036)
58. Crits-Christoph P., Newberg A., Wintering N., Ploessl K., Gibbons M. B., Ring-Kurtz S., Gallop R., Present J., Dopamine transporter levels in cocaine dependent subjects. Drug and Alcohol Dependence 2008 98 1-2 70 76
59. Yeh T. L., Chen K. C., Lin S. H., Availability of dopamine and serotonin transporters in opioid-dependent usersa two-isotope SPECT study Psychopharmacology 2012 220 1 55 64
60. Yang Y. K., Yao W. J., Yeh T. L., Lee I. H., Chen P. S., Lu R. B., Chiu N. T., Decreased dopamine transporter availability in male smokersa dual isotope SPECT study Progress in Neuro-Psychopharmacology and Biological Psychiatry 2008 32 1 274 279
61. Newberg A., Lerman C., Wintering N., Ploessl K., Mozley P. D., Dopamine transporter binding in smokers and nonsmokers Clinical Nuclear Medicine 2007 32 6 452 455 (Pubitemid 46791464)
62. Krause K. H., Dresel S. H., Krause J., la Fougere C., Ackenheil M., The dopamine transporter and neuroimaging in attention deficit hyperactivity disorder Neuroscience and Biobehavioral Reviews 2003 27 7 605 613 (Pubitemid 37414909)
63. Krause J., SPECT and PET of the dopamine transporter in attention-deficit/hyperactivity disorder Expert Review of Neurotherapeutics 2008 8 4 611 625 (Pubitemid 351551013)
64. Dresel S., Krause J., Krause K. H., LaFougere C., Brinkbumer K., Kung H. F., Hahn K., Tatsch K., Attention deficit hyperactivity disorder: binding of [ 99 m Tc ]TRODAT-1 to the dopamine transporter before and after methylphenidate treatment European Journal of Nuclear Medicine 2000 27 10 1518 1524
65. Krause K. H., Dresel S. H., Krause J., Kung H. F., Tatsch K., Increased striatal dopamine transporter in adult patients with attention deficit hyperactivity disorder: effects of methylphenidate as measured by single photon emission computed tomography Neuroscience Letters 2000 285 2 107 110 (Pubitemid 30227631)
66. Krause J., la Fougere C., Krause K. H., Ackenheil M., Dresel S. H., Influence of striatal dopamine transporter availability on the response to methylphenidate in adult patients with ADHD European Archives of Psychiatry and Clinical Neuroscience 2005 255 6 428 431 (Pubitemid 43029831)
67. La Fougre C., Krause J., Krause K. H., Josef Gildehaus F., Hacker M., Koch W., Hahn K., Tatsch K., Dresel S., Value of 99 m Tc -TRODAT-1 SPECT to predict clinical response to methylphenidate treatment in adults with attention deficit hyperactivity disorder Nuclear Medicine Communications 2006 27 9 733 737 (Pubitemid 44213031)
68. Krause K. H., Dresel S. H., Krause J., Kung H. F., Tatsch K., Ackenheil M., Stimulant-like action of nicotine on striatal dopamine transporter in the brain of adults with attention deficit hyperactivity disorder International Journal of Neuropsychopharmacology 2002 5 2 111 113 (Pubitemid 34662972)
69. Dougherty D. D., Bonab A. A., Spencer T. J., Rauch S. L., Madras B. K., Fischman A. J., Dopamine transporter density in patients with attention deficit hyperactivity disorder The Lancet 1999 354 9196 2132 2133 (Pubitemid 30008900)
70. Cheon K. A., Ryu Y. H., Kim Y. K., Namkoong K., Kim C. H., Lee J. D., Dopamine transporter density in the basal ganglia assessed with [ 123 I]IPT SPET in children with attention deficit hyperactivity disorder European Journal of Nuclear Medicine and Molecular Imaging 2003 30 2 306 311 (Pubitemid 36686852)
71. Abi-Dargham A., Mawlawi O., Lombardo I., Gil R., Martinez D., Huang Y., Hwang D. R., Keilp J., Kochan L., van Heertum R., Gorman J. M., Laruelle M., Prefrontal dopamine D1 receptors and working memory in schizophrenia Journal of Neuroscience 2002 22 9 3708 3719 (Pubitemid 37465776)
72. Okubo Y., Suhara T., Suzuki K., Kobayashi K., Inoue O., Terasaki O., Someya Y., Sassa T., Sudo Y., Matsushima E., Iyo M., Tateno Y., Toru M., Decreased prefrontal dopamine D1 receptors in schizophrenia revealed by PET Nature 1997 385 6617 634 635 (Pubitemid 27087576)
73. Karlsson P., Farde L., Halldin C., Sedvall G., PET study of D1 dopamine receptor binding in neuroleptic-naive patients with schizophrenia American Journal of Psychiatry 2002 159 5 761 767 (Pubitemid 34465049)
74. Volkow N. D., Fowler J. S., Wang G. J., The addicted human brain viewed in the light of imaging studies: brain circuits and treatment strategies Neuropharmacology 2004 47 supplement 1 S3 S13
75. Volkow N. D., Fowler J. S., Wang G. J., Swanson J. M., Telang F., Dopamine in drug abuse and addiction: results of imaging studies and treatment implications Archives of Neurology 2007 64 11 1575 1579 (Pubitemid 350106758)
76. Volkow N. D., Fowler J. S., Wang G. J., Swanson J. M., Dopamine in drug abuse and addiction: results from imaging studies and treatment implications Molecular Psychiatry 2004 9 6 557 569 (Pubitemid 38850435)
77. Volkow N. D., Fowler J. S., Wang G. J., Baler R., Telang F., Imaging dopamine's role in drug abuse and addiction Neuropharmacology 2009 56 supplement 1 S3 S8
78. Volkow N. D., Wang G. J., Fowler J. S., Logan J., Gatley S. J., Wong C., Hitzemann R., Pappas N. R., Reinforcing effects of psychostimulants in humans are associated with increases in brain dopamine and occupancy of D 2 receptors Journal of Pharmacology and Experimental Therapeutics 1999 291 1 409 415 (Pubitemid 29451617)
79. Volkow N. D., Wang G. J., Fowler J. S., Logan J., Gatley S. J., Gifford A., Hitzemann R., Ding Y. S., Pappas N., Prediction of reinforcing responses to psychostimulants in humans by brain dopamine D 2 receptor levels American Journal of Psychiatry 1999 156 9 1440 1443 (Pubitemid 29416545)
80. Volkow N. D., Wang G. J., Fischman M. W., Foltint R. W., Fowler J. S., Abumrad N. N., Vitkun S., Logan J., Gatley S. J., Pappas N., Hitzemann R., Shea C. E., Relationship between subjective effects of cocaine and dopamine transporter occupancy Nature 1997 386 6627 827 830 (Pubitemid 27181255)
81. Volkow N. D., Fowler J. S., Wang G. J., Hitzemann R., Logan J., Schlyer D. J., Dewey S. L., Wolf A. P., Decreased dopamine D 2 receptor availability is associated with reduced frontal metabolism in cocaine abusers Synapse 1993 14 2 169 177 (Pubitemid 23157765)
82. Volkow N. D., Chang L., Wang G. J., Fowler J. S., Ding Y. S., Sedler M., Logan J., Franceschi D., Gatley J., Hitzemann R., Gifford A., Wong C., Pappas N., Low level of brain dopamine D 2 receptors in methamphetamine abusers: association with metabolism in the orbitofrontal cortex American Journal of Psychiatry 2001 158 12 2015 2021 (Pubitemid 33104107)
83. Wang G. J., Volkow N. D., Fowler J. S., Logan J., Abumrad N. N., Hitzemann R. J., Pappas N. S., Pascani K., Dopamine D 2 receptor availability in opiate-dependent subjects before and after naloxone-precipitated withdrawal Neuropsychopharmacology 1997 16 2 174 182 (Pubitemid 27086432)
84. Volkow N. D., Wang G. J., Fowler J. S., Logan J., Hitzemann R., Ding Y. S., Pappas N., Shea C., Piscani K., Decreases in dopamine receptors but not in dopamine transporters in alcoholics Alcoholism: Clinical and Experimental Research 1996 20 9 1594 1598 (Pubitemid 26428110)
85. Volkow N. D., Wang G., Fowler J. S., Logan J., Gerasimov M., Maynard L., Ding Y., Gatley S. J., Gifford A., Franceschi D., Therapeutic doses of oral methylphenidate significantly increase extracellular dopamine in the human brain The Journal of Neuroscience 2001 21 2
86. Volkow N. D., Wang G. J., Fowler J. S., Logan J., Franceschi D., Maynard L., Ding Y. S., Gatley S. J., Gifford A., Zhu W., Swanson J. M., Relationship between blockade of dopamine transporters by oral methylphenidate and the increases in extracellular dopamine: therapeutic implications Synapse 2002 43 3 181 187 (Pubitemid 34087672)
87. Farde L., Pauli S., Hall H., Eriksson L., Halldin C., Hgberg T., Nilsson L., Sjgren I., Stone-Elander S., Stereoselective binding of 11C-raclopride in living human braina search for extrastriatal central D-2 dopamine receptors by PET Psychopharmacology 1988 94 4 471 478 (Pubitemid 18087395)
88. Nord M., Farde L., Antipsychotic occupancy of dopamine receptors in schizophrenia CNS Neuroscience and Therapeutics 2011 17 2 97 103
89. Kasper S., Tauscher J., Kfferle B., Barnas C., Pezawas L., Quiner S., Dopamine- and serotonin-receptors in schizophrenia: results of imaging-studies and implicationsfor pharmacotherapy in schizophrenia European Archives of Psychiatry and Clinical Neuroscience 1999 249 supplement 4 S83 S89
90. Abi-Dargham A., Rodenhiser J., Printz D., Zea-Ponce Y., Gil R., Kegeles L. S., Weiss R., Cooper T. B., Mann J. J., van Heertum R. L., Gorman J. M., Laruelle M., Increased baseline occupancy of D 2 receptors by dopamine in schizophrenia Proceedings of the National Academy of Sciences of the United States of America 2000 97 14 8104 8109 (Pubitemid 30460780)
91. Tauscher J., Kfferle B., Asenbaum S., Tauscher-Wisniewski S., Kasper S., Striatal dopamine-2 receptor occupancy as measured with [ 123 I]iodobenzamide and SPECT predicted the occurrence of EPS in patients treated with atypical antipsychotics and haloperidol Psychopharmacology 2002 162 1 42 49 (Pubitemid 34639555)
92. Kasper S., Tauscher J., Kfferle E., Hesselmann B., Barnas C., Brcke T., IBZM-SPECT imaging of dopamine D 2 receptors with typical and atypical antipsychotics European Psychiatry 1998 13 supplement 1 S9 S14
93. Okamura N., Villemagne V. L., Drago J., Pejoska S., Dhamija R. K., Mulligan R. S., Ellis J. R., Ackermann U., O'Keefe G., Jones G., Kung H. F., Pontecorvo M. J., Skovronsky D., Rowe C. C., In vivo measurement of vesicular monoamine transporter type 2 density in Parkinson disease with 18 F-AV-133 Journal of Nuclear Medicine 2010 51 2 223 228
94. Villemagne V. L., Okamura N., Pejoska S., Drago J., Mulligan R. S., Chételat G., Ackermann U., O'Keefe G., Jones G., Gong S., Tochon-Danguy H., Kung H. F., Masters C. L., Skovronsky D. M., Rowe C. C., In vivo assessment of vesicular monoamine transporter type 2 in dementia with lewy bodies and Alzheimer disease Archives of Neurology 2011 68 7 905 912
95. Kung H. F., Guo Y. Z., Billings J., Xu X., Mach R. H., Blau M., Ackerhalt E; R., Preparation and biodistribution of [ 125 I]IBZM: a potential CNS D-2 dopamine receptor imaging agent International Journal of Radiation Applications and Instrumentation B 1988 15 2 195 201 (Pubitemid 18035185)
96. Kung H. F., Pan S., Kung M. P., Billings J., Kasliwal R., Reilley J., Alavi A., In vitro and in vivo evaluation of [ 123 I]IBZM: a potential CNS D-2 dopamine receptor imaging agent Journal of Nuclear Medicine 1989 30 1 88 92 (Pubitemid 19033920)
97. Pinborg L. H., Videbaek C., Ziebell M., Mackeprang T., Friberg L., Rasmussen H., Knudsen G. M., Glenthoj B. Y., [ 123 I]epidepride binding to cerebellar dopamine D 2 /D 3 receptors is displaceable: implications for the use of cerebellum as a reference region Neuroimage 2007 34 4 1450 1453 (Pubitemid 46201908)
98. Bohnen N. I., Frey K. A., Imaging of cholinergic and monoaminergic neurochemical changes in neurodegenerative disorders Molecular Imaging and Biology 2007 9 4 243 257 (Pubitemid 47028740)
99. Lu W., Wolf M. E., Expression of dopamine transporter and vesicular monoamine transporter 2 mRNAs in rat midbrain after repeated amphetamine administration Molecular Brain Research 1997 49 1-2 137 148 (Pubitemid 27453124)
100. Lin K. J., Weng Y. H., Wey S. P., Hsiao I. T., Lu C. S., Skovronsky D., Chang H. P., Kung M. P., Yen T. C., Whole-body biodistribution and radiation dosimetry of 18 F-FP-(+) -DTBZ (18 F-AV-133): a novel vesicular monoamine transporter 2 imaging agent Journal of Nuclear Medicine 2010 51 9 1480 1485
101. Gelb D. J., Oliver E., Gilman S., Diagnostic criteria for Parkinson disease Archives of Neurology 1999 56 1 33 39 (Pubitemid 29046907)
102. Tolosa E., Wenning G., Poewe W., The diagnosis of Parkinson's disease The Lancet Neurology 2006 5 1 75 86 (Pubitemid 41790698)
103. Pahwa R., Lyons K. E., Early diagnosis of Parkinson's disease: recommendations from diagnostic clinical guidelines The American Journal of Managed Care 2010 16 supplement 4 S94 99
104. Hughes A. J., Daniel S. E., Blankson S., Lees A. J., A clinicopathologic study of 100 cases of Parkinson's disease Archives of Neurology 1993 50 2 140 148 (Pubitemid 23054795)
105. Rajput A. H., Rozdilsky B., Rajput A., Accuracy of clinical diagnosis in Parkinsonisma prospective study Canadian Journal of Neurological Sciences 1991 18 3 275 278
106. Antonini A., Imaging for early differential diagnosis of parkinsonism The Lancet Neurology 2010 9 2 130 131
107. Felicio A. C., Shih M. C., Godeiro-Junior C., Andrade L. A. F., Bressan R. A., Ferraz H. B., Molecular imaging studies in Parkinson disease reducing diagnostic uncertainty Neurologist 2009 15 1 6 16
108. Vlaar A. M. M., de Nijs T., Kessels A. G. H., Vreeling F. W., Winogrodzka A., Mess W. H., Tromp S. C., van Kroonenburgh M. J. P. G., Weber W. E. J., Diagnostic value of 123 I-ioflupane and 123 I- iodobenzamide SPECT scans in 248 patients with Parkinsonian syndromes European Neurology 2008 59 5 258 266 (Pubitemid 351561095)
109. Thanvi B., Lo N., Robinson T., Vascular parkinsonisman important cause of parkinsonism in older people Age and Ageing 2005 34 2 114 119 (Pubitemid 40331090)
110. Berry A. L., Foltynie T., Gene therapy: a viable therapeutic strategy for Parkinson's disease? Journal of Neurology 2010 258 2 179 188
111. Leriche L., Bjrklund T., Breysse N., Besret L., Grégoire M. C., Carlsson T., Dollé F., Mandel R. J., Déglon N., Hantraye P., Kirik D., Positron emission tomography imaging demonstrates correlation between behavioral recovery and correction of dopamine neurotransmission after gene therapy Journal of Neuroscience 2009 29 5 1544 1553
112. Kaplitt M. G., Feigin A., Tang C., Fitzsimons H. L., Mattis P., Lawlor P. A., Bland R. J., Young D., Strybing K., Eidelberg D., During M. J., Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: an open label, phase I trial The Lancet 2007 369 9579 2097 2105 (Pubitemid 46935946)
113. Volkow N. D., Wang G. J., Fowler J. S., Logan J., Gatley S. J., Hitzemann R., Chen A. D., Dewey S. L., Pappas N., Decreased striatal dopaminergic responsiveness in detoxified cocaine-dependent subjects Nature 1997 386 6627 830 833 (Pubitemid 27181256)
114. Volkow N. D., Ding Y. S., Fowler J. S., Wang G. J., Logan J., Gatley J. S., Dewey S., Ashby C., Liebermann J., Hitzemann R., Wolf A. P., Is methylphenidate like cocaine? Studies on their pharmacokinetics and distribution in the human brain Archives of General Psychiatry 1995 52 6 456 463
115. Solanto M. V., Neuropsychopharmacological mechanisms of stimulant drug action in attention-deficit hyperactivity disorder: a review and integration Behavioural Brain Research 1998 94 1 127 152 (Pubitemid 28352470)
116. Abi-Dargham A., Do we still believe in the dopamine hypothesis? New data bring new evidence International Journal of Neuropsychopharmacology 2004 7 supplement 1 S1 S5
117. Langer O., Halldin C., PET and SPET tracers for mapping the cardiac nervous system European Journal of Nuclear Medicine 2002 29 3 416 434 (Pubitemid 34253256)
118. Takano A., The application of PET technique for the development and evaluation of novel antipsychotics Current Pharmaceutical Design 2010 16 3 371 377
119. Hiemke C., Therapeutic drug monitoring in neuropsychopharmacology: does it hold its promises? European Archives of Psychiatry and Clinical Neuroscience 2008 258 supplement 1 S21 S27
120. Kapur S., Zipursky R., Jones C., Remington G., Houle S., Relationship between dopamine D 2 occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia American Journal of Psychiatry 2000 157 4 514 520 (Pubitemid 30191189)